Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia T Greipp

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 2, 2017
Molecular testing for the clinical diagnosis of fibrolamellar carcinomaRondell P Graham, Matthew M Yeh, Dora Lam-Himlin, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|April 21, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLWei Ding, Betsy R LaPlant, Timothy G Call, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Advances|May 23, 2020
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Rhett P Ketterling, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 2, 2017
Molecular testing for the clinical diagnosis of fibrolamellar carcinomaRondell P Graham, Matthew M Yeh, Dora Lam-Himlin, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Blood|March 12, 2025
Large-scale dependency and drug screens characterize the therapeutic vulnerabilities of Multiple Myeloma with 1qRomanos Sklavenitis-Pistofidis, Elizabeth D Lightbody, Mairead Reidy, et al.
American Journal of Hematology|April 28, 2021
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.
Blood|April 21, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLWei Ding, Betsy R LaPlant, Timothy G Call, et al.
Blood Advances|March 14, 2025
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsMithun Vinod Shah, Kevin Hung, Anmol Baranwal, et al.
Pageof 13